An Open-Labeled Exploratory Study to Evaluate Safety and Efficacy of FB825 in Adults With Atopic Dermatitis
Condition: Atopic Dermatitis Intervention: Drug: FB825, FB825-15D11, Anti-CemX Sponsor: Fountain Biopharma Inc. Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials